Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
7.55
+0.17 (2.30%)
At close: Dec 31, 2025, 4:00 PM EST
7.70
+0.15 (1.99%)
After-hours: Dec 31, 2025, 6:20 PM EST
Nuvectis Pharma Employees
Nuvectis Pharma had 13 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,138,846
Market Cap
193.39M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | 2 | 18.18% |
| Dec 31, 2022 | 11 | 3 | 37.50% |
| Dec 31, 2021 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NVCT News
- 15 days ago - Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC - GlobeNewsWire
- 5 weeks ago - Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC - GlobeNewsWire
- 2 months ago - CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 2 months ago - Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 4 months ago - Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 5 months ago - Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 - GlobeNewsWire
- 5 months ago - Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 5 months ago - Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study - GlobeNewsWire